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Abstract
In the early phase development of molecularly targeted agents (MTAs), a commonly encountered 
situation is that the MTA is expected to be more effective for a certain biomarker subgroup, say 
marker-positive patients, but there is no adequate evidence to show that the MTA does not work 
for the other subgroup, i.e., marker-negative patients. After establishing that marker-positive 
patients benefit from the treatment, it is often of great clinical interest to determine whether the 
treatment benefit extends to marker-negative patients. The authors propose optimal sequential 
enrichment (OSE) designs to address this practical issue in the context of phase II clinical trials. 
The OSE designs evaluate the treatment effect first in marker-positive patients and then in marker-
negative patients if needed. The designs are optimal in the sense that they minimize the expected 
sample size or the maximum sample size under the null hypothesis that the MTA is futile. An 
efficient, accurate optimization algorithm is proposed to find the optimal design parameters. One 
important advantage of the OSE design is that the go/no-go interim decision rules are specified 
prior to the trial conduct, which makes the design particularly easy to use in practice. A simulation 
study shows that the OSE designs perform well and are ethically more desirable than the 
commonly used marker-stratified design. The OSE design is applied to an endometrial carcinoma 
trial.
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1. Introduction
Personalized or precision medicine is revolutionizing medical research. The premise of 
precision medicine is that patients are heterogeneous and respond differently to treatment 
agents known as molecularly targeted agents (MTAs). The development of MTAs relies on 
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biomarkers that identify a sensitive subgroup (of patients) who will favorably respond to the 
treatment. It is assumed that one or a set of biomarkers has been selected to use in 
classifying patients into two subgroups, generically referred to as a marker-positive group 
and a marker-negative group, and that the marker-positive group presumably responds more 
favorably to the MTA (e.g., the marker-positive patients bear the genomic aberration that the 
MTA targets). If there are established evidences from the biological and clinical studies 
assuring that the biomarkers are truly predictive, the study population should be limited to 
the marker-positive patients to evaluate the treatment effect of the MTA using the 
enrichment trial design. However, at the early phase of the clinical development of MTAs, 
such as phase II clinical trials, a common issue is that there is a substantial amount of 
uncertainty about the ability of the biomarkers to identify the true sensitive subgroup. 
Therefore, after establishing that marker-positive patients benefit from the treatment, it is 
often of great clinical interest to determine whether the treatment benefit extends to marker-
negative patients; otherwise, a large subset of the patient population will be deprived of 
beneficial treatment if the treatment actually is effective for the marker-negative patients. 
The objective of this article is to develop a optimal sequential enrichment (OSE) design to 
tackle the above practical issue in single-arm phase II clinical trials with binary outcomes.
Simon’s optimal two-stage design is arguably the most commonly used phase II clinical trial 
design to test the treatment effect [1]. That design uses an interim look to enhance the 
individual ethics of the trial: if the number of responses at the interim look is less than a 
certain cutoff, the trial should be terminated early to avoid treating more patients with an 
ineffective agent. Simon’s design focuses on the treatment effect for the overall population 
and thus is not suitable for testing the efficacy of MTAs in the presence of subgroups.
To handle MTAs, a straightforward extension of Simon’s optimal design is to stratify the 
patients by their biomarker status, and then apply two parallel, independent Simon’s two-
stage designs to each of the strata (i.e., the marker-positive group and the marker-negative 
group). This design is known as the marker-stratified design (MSD) [2, 3], and has been 
frequently used to investigate a variety of MTAs [4, 5]. Although the MSD allows for the 
evaluation of the treatment effect for both marker-positive and marker-negative groups, it 
ignores the fact that in many applications, clinicians are interested in testing the treatment 
effect in marker-negative patients (i.e., whether the treatment benefit can extend to marker-
negative patients) only after they have established that the MTA is effective for marker-
positive patients. The rationale is that as the MTA targets genomic aberrations that are 
enriched in marker-positive patients, the MTA is expected to be more effective in those 
patients than in patients who do not show that particular genomic enrichment. If the MTA 
does not work for marker-positive patients, it is unlikely to benefit marker-negative patients 
and thus there is no need to test it in that group of patients from the viewpoint of both ethics 
and economics.
The OSE design is developed to handle the case in which the MTA is expected to be more 
effective in marker-positive patients, but there is no definite evidence to show that the 
treatment benefit of the MTA potentially extends to marker-negative patients, which is 
particularly common in early phase drug development. As illustrated in Figure 1, marker-
positive and marker-negative groups are treated sequentially under the OSE design. The 
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proposed design starts from the marker-positive group, using one interim analysis and one 
final analysis for marker-positive patients to evaluate treatment efficacy. If the trial fails to 
achieve certain efficacy requirements at any of the analyses, the trial is terminated and no 
marker-negative patients will be treated. If the trial passes these two analyses, the trial 
proceeds to test the marker-negative patients, during which an interim check and a final 
analysis will be performed. In the OSE design, the interim decision rules are chosen to 
optimize a certain utility function (e.g., the expected sample size under the null hypothesis 
that the MTA is not effective), while controlling the subgroup-specific type I and II error 
rates. As shown later, similar to Simon’s optimal design, one important advantage of the 
OSE design is that the go/no-go decision rules can be enumerated prior to the trial conduct, 
which makes the design particularly easy to use in practice.
The OSE design is motivated by a phase II clinical trial at MD Anderson Cancer Center for 
patients diagnosed with endometrial carcinoma. The MTA used in that trial is a 
phosphatidylinositol 3-kinase (PI3K) inhibitor. Patients are classified into marker-positive or 
marker-negative groups on the basis of their PI3K pathway activation scores [6]. Because the 
marker-positive patients have higher degrees of PI3K pathway activation, the MTA is 
expected to perform better in the marker-positive patients than in the marker-negative 
patients. The objective of this phase II trial is to investigate the efficacy of the MTA for 
marker-positive patients, and possibly for marker-negative patients if the MTA is shown to 
be effective for the marker-positive patients.
The rest of this article is organized as follows. The OSE design is proposed and a 
computationally efficient algorithm is developed to optimize the design parameters in 
Section 2. In Section 3, comprehensive simulation studies are carried out to investigate the 
operating characteristics of the proposed design and compare them to those of the MSD. In 
Section 4, the OSE design is applied to the motivating trial. A brief discussion and 
concluding remarks is provided in Section 5.
2. Optimal Sequential Enrichment Design
2.1. Design
Consider a phase II trial with a binary efficacy endpoint. Let p+ denote the response rate for 
the marker-positive patients and p− denote the response rate for the marker-negative patients 
with the assumption p+ ≥ p− to reflect that the MTA is expected to be more effective for the 
marker-positive patients. Let p0 denote the highest unacceptable response rate such that the 
MTA is deemed futile, and let p1 and p2 denote the lowest acceptable response rates such 
that the MTA is promising for further development for marker-positive and marker-negative 
patients, respectively. In practice, p1 is often equal to p2. The interest of the OSE is to testing 
the following two pairs of subgroup-specific hypotheses:
(1)
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(2)
where the first pair of hypotheses tests whether the MTA is promising for marker-positive 
patients, and the second pair of hypotheses tests whether the MTA is promising for marker-
negative patients. Under the assumption p+ ≥ p−, if  is failed to reject,  is failed to 
reject automatically; however, if  is rejected, it may not be able to reject .
The OSE design evaluates the treatment effect of the MTA first in marker-positive patients 
and then in marker-negative patients if needed. As illustrated in Figure 1 and enumerated 
below, the OSE design has 4 stages. The first two stages concern marker-positive patients 
and the last two stages concern marker-negative patients:
1. Enroll  marker-positive patients. If the number of responses , 
move to the next stage. Otherwise, terminate the trial and conclude that the 
MTA is not effective for the overall population, including both marker-
positive and marker-negative patients (i.e., fail to reject  and ).
2. Enroll an additional  marker-positive patients. Out of the total of 
 enrolled marker-positive patients, if the number of responses 
X+ > r+,  is rejected, claiming that the drug is effective for marker-
positive patients, and initiate the next stage with marker-negative patients. 
Otherwise, the trial is terminated and the conclusion is that the MTA is not 
effective for the overall population.
3. Enroll  marker-negative patients. If the number of responses , 
move to the next stage. Otherwise, terminate the trial and conclude that the 
MTA is not effective for marker-negative patients (i.e., fail to reject ), 
but effective for marker-positive patients (i.e., reject ).
4. Enroll an additional  marker-negative patients. Out of the total of 
 enrolled marker-negative patients, if the number of response 
X− > r−,  is rejected and the drug is effective for the overall population 
(i.e., reject both  and ); otherwise, the conclusion is that the MTA is 
not effective for marker-negative patients, but is still effective for marker-
positive patients.
2.2. Methods
The operating characteristics of the OSE design depend on four pairs of design parameters, 
( ), (r+, n+), ( ), and (r−, n−). Let  and . 
The values of (r,n) are chose to minimize the expected total number of patients under the 
null hypothesis p+ = p− = p0, while controlling the subgroup-specific type I and II error rates 
at certain prespecified levels. It is worthy noting that the null hypothesis p+ = p− = p0 is only 
used for the purpose of minimizing the expected total number of patients, not for defining 
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type I error. The type I error that the design aims to control is the subgroup-specific type I 
errors, defined under subgroup-specific null hypotheses (1) and (2). Thus, the closed testing 
procedure [7, 8] is not applicable here.
Let α+ and α− denote the desirable subgroup-specific type I error rates for marker-positive 
and marker-negative patients, respectively; and β+ and β− denote the desirable subgroup-
specific type II error rates for marker-positive and marker-negative patients. Because 
marker-positive patients and marker-negative patients are tested squentially, if we fail to 
reject , we automatically fail to reject . As a result, β− > β+ by design. This seems 
restrictive, but actually no different from the standard clinical trial paradigm, where the drug 
moves to phase III for testing only when the test in phase II is positive. In other words, if we 
view phase II and III trials as a single drug testing process, the type II error of phase III must 
be greater than that of phase II because if we fail to reject null in phase II, we automatically 
fail to reject the null in phase III. Let  and X+ be the numbers of responses at the first and 
second interim analyses among marker-positive patients, and let  and X− be the number 
of responses at the third interim analysis and the final analysis among marker-negative 
patients. The design parameters (r,n) must satisfy the following type I and type II error 
constraints:
(3)
(4)
(5)
(6)
where the first two conditions define the type I and II error requirements for the test of the 
treatment effect for marker-positive patients, and the last two conditions define the type I 
and II error requirements for the test of the treatment effect for marker-negative patients. 
Noting that  and  follow independent binomial distributions 
and defining , it follows that the above constraints 
can be expressed as
Zang and Yuan Page 5
Stat Med. Author manuscript; available in PMC 2018 January 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Let S(r,n | p0, p1, p2, α+, α−, β+, β−) denote the set of all possible values of (r,n) that satisfy 
the type I and II error constraints. The goal of the OSE design is to find (r*,n*) ∈ S(r,n | p0, 
p1, p2, α+, α−, β+, β−) that minimizes the expected total sample size E(n|p0) under the null 
hypothesis p+ = p− = p0 (i.e., the MTA is not effective for both marker-positive and marker-
negative patients),
(7)
Letting PETi(p) denote the probability of early termination after the ith stage when the 
response rate is p, E(n|p0) is given by
(8)
where
2.3. Optimization algorithm
In principle, an exhaustive numerical search can be conducted to optimize the objective 
function (7) and find the optimal design parameters (r*,n*), which is the approach adopted 
by Simon’s optimal two-stage design. This bruteforce approach, however, is not suitable in 
the OSE case because of the larger search space: simultaneous grid searching for 8 design 
parameters is extremely computationally expensive. To speed the optimization process, the 
authors propose a divide-and-conquer algorithm, which divides the optimization problem 
into two lower dimension optimization problems, and then they are optimized one by one. 
The divide-and-conquer algorithm is based on the following decomposition of the expected 
total sample size:
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where E(n+|p0) and E(n−|p0) are the expected sample sizes under p+ = p0 and p− = p0 for 
marker-positive and marker-negative patients, respectively. In other words, the overall 
expected sample size can be decomposed into the expected sample sizes for marker-positive 
and marker-negative patients from two separate trials.
Thus, the authors propose to minimize E(n|p0) by first minimizing E(n+|p0), and then, 
conditional on the optimal solution of E(n+|p0), minimizing E(n−|p0). Strictly speaking, this 
two-step optimization procedure does not guarantee that its solution is globally optimal 
because E(n+|p0) and E(n−|p0) are correlated through PET2(p0). However, in practice, the 
solution yielded by the above procedure almost always matches the global optimal solution. 
The key observation is that {1 − PET2(p0)} is the type I error rate for the marker-positive 
patients (i.e., α+), which is typically small, e.g., 0.1 or 0.05. As a result, E(n|p0) is 
predominantly determined by the value of E(n+|p0), and thus E(n|p0) is approximately 
optimized when E(n+|p0) is optimized. Among all possible solutions that minimize E(n+|p0), 
the solution provided by the proposed algorithm is optimal in minimizing E(n|p0). This is 
verified by the numerical studies described later, which find that almost all the solutions 
from the proposed optimization algorithm match the global optimization solution. However, 
the proposed divide-and-conquer algorithm reduces the computation time by over 20-fold.
The optimization of E(n+|p0) is straightforward because it is exactly the same as Simon’s 
optimal two-stage design, noting that both the type I and II requirements (3) and (4) and 
objection function E(n+|p0) do not depend on the marker-negative patients. Let 
( ) and ( ) denote the solution that minimizes E(n+|p0). Then, given 
( ) and ( ), the optimization of E(n−|p0) is determined by choosing 
appropriate values of ( ) and (r−, n−) that satisfy the type I and type II requirements (5) 
and (6).
Optimizing E(n−|p0) is less straightforward because the corresponding type I and II error 
requirements (5) and (6) depend on the design parameters of the marker-positive patients. 
That is, the part of the two-stage design that evaluates the treatment effect for marker-
negative patients is not an independent, stand-alone, two-stage design, but rather depends on 
the part of the design that evaluates the treatment effect for marker-positive patients. The 
strategy is to reformulate the problem such that the part of the two-stage design that 
evaluates the treatment effect for marker-negative patients can be viewed as an independent, 
stand-alone, two-stage design. This is based on the results that follow (the proof of Lemma 1 
is provided in the Appendix).
Lemma 1—Controlling the type I error rate and the type II error rate of the marker-negative 
group so that they are no greater than α− and β−, respectively, is equivalent to controlling
(9)
Zang and Yuan Page 7
Stat Med. Author manuscript; available in PMC 2018 January 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(10)
Noting that the left sides of equations (9) and (10) are the definitions of type I and II error 
rates for an independent two-stage design for marker-negative patients, the above problem 
can be converted into a standard two-stage design optimization problem: minimize E(n−|p0) 
for an independent two-stage design (for marker-negative patients) while controlling the type 
I and II error rates at the respective levels of
where α* and β* can be viewed as the adjusted type I and type II error rates, accounting for 
the sequential testing procedure (i.e., marker-negative patients are tested after marker-
positive patients). Given the values of ( ) and ( ), the value of β* can be 
easily calculated, noting that X+ and  follow binomial distributions.
The difficulty is that α* depends on the response rate of the marker-positive patients (i.e., 
p+), which is typically unknown at the design stage. To circumvent that issue, the authors 
propose to replace p+ with its upper bound u, and calculate the adjusted type I error rate as
(11)
In practice, the value of u can be elicited from physicians. For example, for a certain 
treatment, physicians may expect that the response rate is unlikely to be higher than u = 
60%. Typically, it is required that u ≥ p1. The validity of the above approach is given by 
Theorem 1.
Theorem 1—Given p+ ≤ u, if the design parameters ( ) and (r−, n−) are chose based 
on the adjusted type I error rate α* as given by (11), the type I error rate for the marker-
negative patients is maintained under level α−.
The proof is provided in the Appendix. One may be concerned about the overly specification 
of u; however, the sensitivity analysis (described later) shows that the OSE design is rather 
robust to the specification of u.
The proposed divide-and-conquer algorithm thus converts the original optimization problem 
into the optimization of two independent, 2-stage designs. The optimal values of ( ) 
and (r+, n+) are obtained by minimizing E(n+|p0) while controlling the type I and type II 
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error rates at α+ and β+. Then, given the optimal values of ( ) and (r+, n+), the optimal 
values of ( ) and (r−, n−) can be obtained by minimizing E(n−|p0) while controlling the 
type I and type II error rates at α* and β*. For convenience, this design is referred to as OSE-
O.
Thus far, the focus is on minimizing the expected total sample size E(n|p0). Alternatively, the 
minimax design can be developed with the aim of minimizing the maximal total sample size. 
That is, instead of minimizing the expected total sample size, the purpose of the minimax 
design is to find (r†, n†) ∈ S(r, n | p0, p1, p2, α+, α−, β+, β−) that minimizes the maximal 
total sample size Max(n|p0) under the null hypothesis p+ = p− = p0,
(12)
The developed divide-and-conquer algorithm can be applied to find the optimal parameter 
(r†, n†) alone the same line. The only modification is to use the maximum sample size to 
replace the expected sample size during the optimization procedure. The resulting minimax 
design is denoted as the OSE-M.
3. Numerical studies
3.1. Operating characteristics of the OSE design
Throughout the numerical studies, the authors fix p1 = p2, as is typically the case in practice, 
i.e., the lowest acceptable response rate for the MTA is the same for marker-positive and 
marker-negative patients. Table 1 provides the operating characteristics of the OSE-O design 
under different values of (p0, p1), including optimal design parameters ( ), (r+, n+), 
( ) and (r−, n−), the minimum expected sample size E(n|p0), and the probabilities of 
early termination PET1, PET2, and PET3. The results are based on analytic calculations with 
u = p1 + 0.3. Under each set of values of (p0, p1), the first, second and third rows correspond 
to different type I and type II requirements (α+, β+, α−, β−) = (0.05, 0.2, 0.05, 0.3), (0.05, 
0.1, 0.05, 0.15) and (0.05, 0.1, 0.05, 0.2), respectively. We are aware that β− should be 
greater than β+ as the error is accumulating from the marker positive group to the marker 
negative group. In general, the OSE-O design terminates the trial early with high 
probabilities when the MTA is futile (i.e., p+ = p− = p0), leading to small sample sizes. For 
example, assuming p0 = 0.1, p1 = p2 = 0.3, and (α+, β+, α−, β−) = (0.05, 0.2, 0.05, 0.3), the 
design parameters for the OSE-O design are , (r+, n+) = (5, 29), 
 and (r−, n−) = (6, 35). Although the maximum sample size for this design is 
64 (i.e., 29 marker-positive patients + 35 marker-negative patients), on average, only about 
16 patients are needed to enroll when the treatment is futile for marker-positive and marker-
negative patients. In this case, the probabilities of early termination up to the first, second 
and third interim analyses are 0.74, 0.95 and 0.98, respectively. To examine the accuracy of 
the proposed divide-and-conquer optimization algorithm, an exhaustive numerical search is 
also used to find the optimal design parameters (results not shown in Table 1 and Table 2). In 
all the scenarios considered in Table 1, the solutions obtained from the two optimization 
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methods all matched, but the computation time of the proposed algorithm was less than 1/20 
of that of the exhaustive numerical search.
Table 2 summarizes the results for the OSE-M (i.e., minimax) design. Due to the different 
optimization criteria, compared to the OSE-O design, the OSE-M design has a smaller 
maximum sample size but a larger expected sample size under p0. For example, comparing 
the first rows between Table 1 and Table 2, the maximum sample size under the OSE-M 
design is 7 patients fewer than that under the OSE-O design. However, on average, the OSE-
M design still recruits about 4.3 more patients than the OSE-O design. Nevertheless, there 
are circumstances for which the OSE-M design may be preferable. For example, when p0 = 
0.2, p1 = 0.4 and (α+, β+, α−, β−) = (0.05, 0.1, 0.05, 0.15), the OSE-M and OSE-O designs 
have almost the same E(n|p0) (33.47 versus 32.27), but the OSE-M design has a smaller 
maximum sample size than the OSE-O design (98 versus 120). More numerical studies with 
p1 − p0 = 0.15 can be found in the supplementary materials with Table S1 representing OSE-
O and Table S2 representing OSE-M.
3.2. Comparison to the MSD
Comprehensive simulation studies are carried out to compare the proposed OSE-O and 
OSE-M designs to the MSD, which stratifies patients into marker-positive and marker-
negative subgroups and then independently applies Simon’s optimal two-stage design to 
each of the two subgroups. Two different versions of MSD are considered: the first one 
minimizes the overall sample size (denoted as MSD-O), and the second one is based on the 
minimax criterion (denoted as MSD-M). Let (α+, β+) = (0.05, 0.1), (α−, β−) = (0.05, 0.2), p0 
= 0.2, p2 = p1 = 0.4 and u = 0.7. Different configurations of the response rates p+ and p− are 
studied. Under each of the response rate configurations, 10,000 simulated trials were 
conducted for each design.
Table 3 summarizes the simulation results, including the power/type I error rate and average 
sample size. Scenarios 1 and 2 consider the cases in which the MTA does not work for both 
marker-positive and marker-negative patients. In these cases, the OSE designs show 
substantial advantage in individual patient ethics by exposing substantially fewer marker-
negative patients to the ineffective treatment. For example, when p+ = p− = 0.2, the OSE 
designs enroll only 1.5 marker-negative patients, on average; whereas the MSD designs 
enroll more than 20 patients, on average. For the marker-positive patients, both the OSE 
designs and MSD designs yield type I error rates close to 5%. Note that for the marker-
negative patients, the OSE designs yielded type I error rates substantially lower than 5%. 
This is because the upper bound u is used (to replace the true value of p+) to calculate the 
adjusted type I error rate α*. If the true value of p+ is used, the type I error rate is about 5% 
(results not shown). This should not be regarded as a drawback because a low type I error 
rate is a desirable property if it does not notably affect the power. In scenarios 3 and 4, the 
MTA is effective for marker-positive patients, but not for marker-negative patients. The OSE 
designs and MSDs have similar performances in terms of the power to detect the treatment 
effect for the marker-positive patients and in controlling the type I error rate for the marker-
negative patients. Scenarios 5 and 6 represent the situation in which the treatment is effective 
for both the marker-positive and marker-negative patients. Compared to the MSDs, the OSE 
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designs enroll approximately 5 more marker-negative patients on average when p+ = p− = 
0.4 (i.e., scenario 5) and 9 more marker-negative patients on average when p+ = 0.5 and p− = 
0.4 (i.e., scenario 6). When the treatment is effective for marker-negative patients, the OSE 
designs remain ethical because more patients benefit from the treatment within the trial. In 
addition, although the OSE designs recruit more patients, they are about 8% more powerful 
than the MSDs in detecting the treatment effect for marker-negative patients in scenario 6. In 
addition, more simulation results with different parameters’ configuration can be found in 
the supplementary materials. Specifically, Table S3 focuses on different lowest acceptable 
response rate of p1 = p2 = 0.35 and Table S4 focuses on different type I and type II error 
requirements of (α+, β+) = (0.1, 0.15) and (α−, β−) = (0.1, 0.2).
In summary, the OSE designs outperform the MSDs with smaller expected sample sizes 
when no treatment effect is expected in both marker-positive and marker-negative 
subgroups. In the case that the treatment is effective for marker-positive patients, the OSE 
designs offer no clear advantage over the MSDs—the OSE designs may result in slightly 
larger sample size and require screening more patients with potentially longer trial time. 
Nevertheless, considering the fact that the success rate of phase II clinical trials is not high 
[9], the OSE designs are still attractive for some applications, for example, when the 
biomarker is cheap to measure and there is considerable uncertainty on efficacy of the 
experimental agents.
3.3. Sensitivity analysis
In the above simulations, u = 0.7 is used as the upper bound of p+ (i.e., the response rate for 
marker-positive patients) to derive the optimal design parameters for the OSE designs. To 
assess the sensitivity to this upper bound, the operating characteristics of the OSE designs 
under different u are also examined, with the value increasing from 0.8 to 1.0, while using 
the same values for the other simulation configurations as those shown in Table 3. The 
results of the sensitivity analysis are shown in Table 4. It is easy to see that the results are 
rather stable across different choices of u and are very close to the results given in Table 3. 
Hence, if there is no empirical data to speculate a value of u a prior, a practical resolution is 
to set u directly at 1.
Table 4 only reports the results where u is correctly specified (greater than p+). Table S5 in 
the supplementary materials investigates the performances of the OSE designs when u is 
mis-specified (less than p+). According to the simulation results, the mis-specified u does 
not affect the power; however; it dose inflate the type I errors. The raise of the type I errors 
are marginal when u is close to p+ (u = 0.4) and are substantial when u is far away from p+ 
(u = 0.2).
Both the OSE designs and MSDs rely on a key prerequisite that an precise biomarker 
classifier exists at the beginning of the trial which can correctly classify every patient into 
either the marker-positive or marker-negative subgroups. However, in practice, such precise 
classifier may not be available considering the exploratory native of the phase II trial. Hence, 
it is important to study the performances of the OSE designs and MSDs in the presence of 
imperfect biomarker classifier. Table 5 summarizes the results of a sensitivity study with a 
non-informative biomarker classifier, which always classifies patients as marker-positive (or 
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marker-negative) with a probability of 50%, regardless the true biomarker status of the 
patients. According to the simulation results, if the treatment is promising or unpromising 
for both biomarker subgroups (Scenarios 1 and 2), the non-informative biomarker classifier 
has little impact on evaluating the treatment. However, if the treatment effect is limited to the 
marker-positive subgroup only (Scenarios 3 and 4), both OSE designs and MSDs fail to 
control type I and type II errors at their nominal levels. Hence, to implement the biomarker-
based clinical designs, such as OSE designs and MSDs, it is important that the biomarker 
classifier is precise and validated. The authors of this manuscript have investigated this issue 
and published a series of papers that handle the biomarker classifier with misclassification 
errors [10, 11, 12, 13].
4. Application
The proposed OSE-O design is applied to the phase II trial to evaluate a PI3K inhibitor in 
endometrial carcinoma. The unacceptable response rate in the trial is p0 = 0.1 and the lowest 
acceptable response rate is p1 = p2 = 0.3. The type I and type II error rates are controlled at 
(α+, β+) = (0.05, 0.2) for marker-positive patients and (α−, β−) = (0.05, 0.4) for marker-
negative patients. Under the OSE-O design, the trial first enroll 10 marker-positive patients. 
If 1 or no patients respond to the PI3K inhibitor, the PIs terminate the trial and conclude that 
the treatment is unpromising; otherwise, 19 more marker-positive patients will be enrolled. 
Among the total 29 marker-positive patients, if 5 or fewer patients respond to the PI3K 
inhibitor, the PIs terminate the trial and conclude that the treatment is unpromising; 
otherwise, the PIs continue the trial to test marker-negative patients, initially enrolling 10 
such patients. If 1 or no patients respond, the PIs terminate the trial and conclude that the 
PI3K inhibitor is effective only for marker-positive patients; otherwise, 12 additional 
marker-negative patients are enrolled. Among the total of 22 marker-negative patients, if 
more than 4 respond to the treatment, the PIs conclude that the PI3K inhibitor is effective for 
both marker-positive and marker-negative patients; otherwise the PI3K inhibitor is effective 
only for marker-positive patients. The maximal sample size under the OSE-O design is 51. 
Under the null hypothesis that the PI3K inhibitor is not effective for both marker-positive 
and marker-negative patients, the trial has 73.6%, 95.3% and 98.8% chance of being 
terminated early at the first, second and third interim checks. Therefore, according to 
equation (8), the expected sample size under the null hypotheses is 10 + 0.264 × 19 + 0.047 
× 10 + 0.012 × 12 = 15.6.
For comparison, the authors also considered the MSD-O design, in which the following 
Simon’s optimal two-stage design is used independently for the marker-positive and marker-
negative patient treatment arms. The marker-positive arm for the MSD-O design is idential 
as that for the OSE-O design. For the marker-negative arm, at the first stage, 3 marker-
negative patients are enrolled. If none of the patients responds, the trial is terminated, 
otherwise the PIs enroll 20 additional marker-negative patients. Out of the total of 23 
marker-negative patients, if more than 4 patients respond, the PIs conclude that the treatment 
is promising; otherwise, the PIs conclude that the treatment is not effective for the marker-
negative patients. The MSD-O design has a maximal sample size of 52, which is comparable 
with the OSE-O design. However, under the null hypothesis that the PI3K inhibitor is not 
effective for both marker-positive and marker-negative patients, the probability of early 
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termination for the marker-positive and marker-negative arms is 73.6% and 72.9% 
respectively. Therefore, the average sample size for the MSD-O design is (10 × 0.74 + 29 × 
0.26) + (3 × 0.73 + 23 × 0.27) = 23.4. Therefore, by adopting the proposed OSE-O design, 
the trial could potentially treat 8 fewer (marker-negative) patients with a futile treatment.
5. Discussion
We have proposed the OSE designs to test the treatment effect of an MTA when it is 
expected that the treatment is more effective for marker-positive patients, but there is no 
adequate evidence to show that the MTA does not work for marker-negative patients. The 
OSE designs test the treatment effect for the marker-positive group first and then test it for 
the marker-negative patients if the MTA is shown to be effective for the marker-positive 
patients. Multiple interim analyses are incorporated into the design to terminate the trial 
early if the MTA is futile. The OSE designs minimize the expected sample size or the 
maximum value of the total sample size, while controlling the type I and II error rates. 
Simulation studies and an application to a endometrial carcinoma trial show that the OSE 
designs possess desirable operating characteristics and enhance the individual ethics of the 
trial. Because the go/no-go interim decision rules of the OSE designs can be enumerated 
prior to the trial conduct, it is particularly easy to use the design in practice.
Although the OSE designs yield desirable operating characteristics and are easy to 
implement, they have some limitations. Compared to the MSD that treats all comers, the 
OSE designs evaluate subgroups sequentially, and thus require to screen more subjects and 
often prolong the trial duration when the treatment is effective for marker-positive patients. 
Therefore, the OSE designs are more suitable for the case that there is substantial 
uncertainty on the efficacy of the experimental agent, or the case that patients can be easily 
screened and limited resource does not allow to treat many patients (all comers) 
simultaneously. Given the fact that most of experimental agents tested in phase II trials 
failed to move to phase III [9], the OSE designs provide an attractive design option for 
testing some MTAs. In addition, the OSE designs are built on the assumption that marker-
positive patients are more likely to benefit from the treatment than marker-negative patients. 
In other words, the biomarker is predictive. The OSE designs are not a good choice when 
little information is available on the predictive ability of the biomarker. They are more 
appropriate for the case that there are strong biological rationale and evidence that the 
biomarker is predictive to a certain degree such that if the MTA does not work for marker-
positive patients, it is less like to work for marker-negative patients.
Within each marker group, the two-stage design is adopted, which can be easily extended to 
three or more stages. However, as the decrease in the sample size from a two-stage design to 
one with three or more stages is limited [14], further extension may not be very useful. A 
more interesting extension is to consider multiple marker groups (larger than 2), with the 
ordinal relationship existing for only part of the groups. Further research in this direction is 
warranted. The proposed designs are appropriate for binary response outcomes. It is also of 
interest to extend the proposed designs to handle other response outcomes, such as time-to-
event outcomes. The sequential designs take advantage of the ordinal relationship between 
two marker groups. If the order is unknown, adopting the sequential design may decrease the 
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power of the test for the marker-negative patients. If this is the case, a parallel test such as 
the stratified design may be more appropriate. Otherwise, a treatment effect comparison 
stage is needed at the beginning of the sequential design to identify the order [15]. However, 
controlling the additional type I and type II errors induced by the comparison stage will 
remain a challenge.
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Refer to Web version on PubMed Central for supplementary material.
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APPENDIX
Proof of Lemma 1
As ( , X+) are independent of ( , X−), the left part of the inequality (5) for the type I 
error is maximized at
Thus, to control this probability so that it is no greater than α−, the following condition is 
needed
Let us turn to the type II error. As p+ ≥ p− ≥ p2, the left part of inequality (6) is maximized at
Hence, to control the type II error so that it remains under β−, it needs
Proof of Theorem 1
B(r, n, p) can be represented in terms of the regularized incomplete beta function as
Then, by taking the derivative of B(r, n, p) with respect to p and get
Hence, B(r, n, p) is monotonically increasing with p, and
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given p+ ≤ u. Therefore, according to Lemma 1, once the adjusted type I error rate is 
controlled at α*, the type I error rate for the marker-negative patients is maintained under 
α−.
Zang and Yuan Page 16
Stat Med. Author manuscript; available in PMC 2018 January 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Diagram of the OSE design.
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